Sphingolipids (SLs) are an integral part of all eukaryotic cellular membranes. In addition, they have indispensable functions as signalling molecules controlling a myriad of cellular events. Disruption of either the de novo synthesis or the degradation pathways has been shown to have detrimental effects. The earlier identification of selective inhibitors of fungal SL biosynthesis promised potent broad-spectrum anti-fungal agents, which later encouraged testing some of those agents against protozoan parasites. In this review we focus on the key enzymes of the SL de novo biosynthetic pathway in protozoan parasites of the Apicomplexa and Kinetoplastidae, outlining the divergence and interconnection between host and pathogen metabolism. The druggability of the SL biosynthesis is considered, alongside recent technology advances that will enable the dissection and analyses of this pathway in the parasitic protozoa. The future impact of these advances for the development of new therapeutics for both globally threatening and neglected infectious diseases is potentially profound.
|Number of pages||14|
|Issue number||Special Issue 2|
|Early online date||22 Jun 2017|
|Publication status||Published - 28 Feb 2018|
|Event||British Society for Parasitology: Autumn Symposium on Microbial Protein Targets - Towards Understanding and Intervention - Durham University, Durham, United Kingdom|
Duration: 14 Sep 2016 → 16 Sep 2016
Mina, J. G. M., & Denny, P. W. (2018). Everybody needs sphingolipids, right! Mining for new drug targets in protozoan sphingolipid biosynthesis. Parasitology, 145(Special Issue 2), 134-147. https://doi.org/10.1017/S0031182017001081